{
    "abstract": "Background In phase III trials, 2 doses of a herpes zoster (HZ) subunit vaccine (HZ/su; 50 \u00b5g varicella-zoster virus glycoprotein E [gE] and AS01B Adjuvant System) administered 2-months apart in older adults (\u226550 and \u226570 years) demonstrated >90% efficacy in preventing HZ and had a clinically acceptable safety profile. Here we report immunogenicity, reactogenicity and safety following administration of 2 HZ/su doses at intervals longer than 2 months. Methods In this Phase III, open-label trial conducted in the US and Estonia, 354 adults \u226550 years were randomized 1:1:1 to receive 2 HZ/su doses 2, 6, or 12 months apart. gE-specific humoral immune responses were evaluated at pre-vaccination, 1 and 12 months post-dose 2. Co-primary objectives were to compare immune responses to HZ/su 1 month post-dose 2 when given 6-months or 12-months apart to those administered 2-months apart. For each participant, safety information was collected from dose 1 to 12 months post-dose 2. Results 346 participants completed the study and 343 were included in the according-to-protocol cohort for immunogenicity. One month post-dose 2, vaccine response rates were 96.5% (97.5% confidence interval [CI]: 90.4; 99.2) and 94.5% (97.5% CI: 87.6; 98.3) for the 0, 6- and 0, 12-month schedules, respectively, both schedules meeting the pre-defined criterion. Non-inferiority of anti-gE geometric mean concentrations was demonstrated for HZ/su administered on 0, 6-month compared to a 0, 2-month schedule; however, HZ/su administered on a 0, 12-month schedule did not meet the non-inferiority criterion. Injection site pain was the most commonly reported solicited adverse event (AE). 26 participants each reported at least 1 serious AE; none were assessed as related to vaccination. Conclusions Immune responses to HZ/su administered at 0, 6-month were non-inferior to those elicited by a 0, 2-month schedule. HZ/su exhibited a clinically acceptable safety profile for all dosing intervals. Clinical Trials Registration: Clinicaltrials.gov (NCT01751165).",
    "author_highlights": [
        {
            "endOffset": 13415,
            "sentence": "2 doses of HZ/su 2 months apart were immunogenic and efficacious against HZ.",
            "startOffset": 13339
        },
        {
            "endOffset": 13495,
            "sentence": "We assessed humoral immunogenicity of 2 HZ/su doses given 6 or 12 months apart.",
            "startOffset": 13416
        },
        {
            "endOffset": 13579,
            "sentence": "Humoral immunogenicity of the 0, 6-month schedule was non-inferior to the 0, 2-one.",
            "startOffset": 13496
        },
        {
            "endOffset": 13658,
            "sentence": "Non-inferiority of the 0, 12- to the 0, 2-month schedule was not demonstrated.",
            "startOffset": 13580
        },
        {
            "endOffset": 13719,
            "sentence": "No safety concerns were identified for any of the schedules.",
            "startOffset": 13659
        }
    ],
    "bib_entries": {
        "b0005": {
            "authors": [
                {
                    "first": "Emily",
                    "initial": "E.",
                    "last": "Eshleman"
                },
                {
                    "first": "Aamir",
                    "initial": "A.",
                    "last": "Shahzad"
                },
                {
                    "first": "Randall J.",
                    "initial": "R.J.",
                    "last": "Cohrs"
                }
            ],
            "doi": "10.2217/fvl.10.90",
            "firstpage": "341",
            "issn": "17460794",
            "lastpage": "355",
            "pub_year": 2011,
            "title": "Varicella zoster virus latency",
            "volume": "6"
        },
        "b0010": {
            "authors": [
                {
                    "first": "Jeffrey I.",
                    "initial": "J.I.",
                    "last": "Cohen"
                }
            ],
            "doi": "10.1056/NEJMcp1302674",
            "firstpage": "255",
            "issn": "00284793",
            "lastpage": "263",
            "pmid": "23863052",
            "pub_year": 2013,
            "title": "Herpes Zoster",
            "volume": "369"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Rafael",
                    "initial": "R.",
                    "last": "Harpaz"
                },
                {
                    "first": "Ismael R.",
                    "initial": "I.R.",
                    "last": "Ortega-Sanchez"
                },
                {
                    "first": "Jane F.",
                    "initial": "J.F.",
                    "last": "Seward"
                }
            ],
            "firstpage": "1",
            "issn": "15458601",
            "lastpage": "CE2",
            "pmid": "18528318",
            "pub_year": 2008,
            "title": "Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).",
            "volume": "57"
        },
        "b0020": {
            "authors": [
                {
                    "first": "M. N.",
                    "initial": "M.N.",
                    "last": "Oxman"
                },
                {
                    "first": "M. J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "G. R.",
                    "initial": "G.R.",
                    "last": "Johnson"
                },
                {
                    "first": "K. E.",
                    "initial": "K.E.",
                    "last": "Schmader"
                },
                {
                    "first": "S. E.",
                    "initial": "S.E.",
                    "last": "Straus"
                },
                {
                    "first": "L. D.",
                    "initial": "L.D.",
                    "last": "Gelb"
                },
                {
                    "first": "R. D.",
                    "initial": "R.D.",
                    "last": "Arbeit"
                },
                {
                    "first": "M. S.",
                    "initial": "M.S.",
                    "last": "Simberkoff"
                },
                {
                    "first": "A. A.",
                    "initial": "A.A.",
                    "last": "Gershon"
                },
                {
                    "first": "L. E.",
                    "initial": "L.E.",
                    "last": "Davis"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Weinberg"
                },
                {
                    "first": "K. D.",
                    "initial": "K.D.",
                    "last": "Boardman"
                },
                {
                    "first": "H. M.",
                    "initial": "H.M.",
                    "last": "Williams"
                },
                {
                    "first": "J. Hongyuan",
                    "initial": "J.H.",
                    "last": "Zhang"
                },
                {
                    "first": "P. N.",
                    "initial": "P.N.",
                    "last": "Peduzzi"
                },
                {
                    "first": "C. E.",
                    "initial": "C.E.",
                    "last": "Beisel"
                },
                {
                    "first": "V. A.",
                    "initial": "V.A.",
                    "last": "Morrison"
                },
                {
                    "first": "J. C.",
                    "initial": "J.C.",
                    "last": "Guatelli"
                },
                {
                    "first": "P. A.",
                    "initial": "P.A.",
                    "last": "Brooks"
                },
                {
                    "first": "C. A.",
                    "initial": "C.A.",
                    "last": "Kauffman"
                },
                {
                    "first": "C. T.",
                    "initial": "C.T.",
                    "last": "Pachucki"
                },
                {
                    "first": "K. M.",
                    "initial": "K.M.",
                    "last": "Neuzil"
                },
                {
                    "first": "R. F.",
                    "initial": "R.F.",
                    "last": "Betts"
                },
                {
                    "first": "P. F.",
                    "initial": "P.F.",
                    "last": "Wright"
                },
                {
                    "first": "M. R.",
                    "initial": "M.R.",
                    "last": "Griffin"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Brunell"
                },
                {
                    "first": "N. E.",
                    "initial": "N.E.",
                    "last": "Soto"
                },
                {
                    "first": "A. R.",
                    "initial": "A.R.",
                    "last": "Marques"
                },
                {
                    "first": "S. K.",
                    "initial": "S.K.",
                    "last": "Keay"
                },
                {
                    "first": "R. P.",
                    "initial": "R.P.",
                    "last": "Goodman"
                },
                {
                    "first": "D. J.",
                    "initial": "D.J.",
                    "last": "Cotton"
                },
                {
                    "first": "J. W.",
                    "initial": "J.W.",
                    "last": "Gnann"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Loutit"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Holodniy"
                },
                {
                    "first": "W. A.",
                    "initial": "W.A.",
                    "last": "Keitel"
                },
                {
                    "first": "G. E.",
                    "initial": "G.E.",
                    "last": "Crawford"
                },
                {
                    "first": "S. S.",
                    "initial": "S.S.",
                    "last": "Yeh"
                },
                {
                    "first": "Z.",
                    "initial": "Z.",
                    "last": "Lobo"
                },
                {
                    "first": "J. F.",
                    "initial": "J.F.",
                    "last": "Toney"
                },
                {
                    "first": "R. N.",
                    "initial": "R.N.",
                    "last": "Greenberg"
                },
                {
                    "first": "P. M.",
                    "initial": "P.M.",
                    "last": "Keller"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Harbecke"
                },
                {
                    "first": "A. R.",
                    "initial": "A.R.",
                    "last": "Hayward"
                },
                {
                    "first": "M. R.",
                    "initial": "M.R.",
                    "last": "Irwin"
                },
                {
                    "first": "T. C.",
                    "initial": "T.C.",
                    "last": "Kyriakides"
                },
                {
                    "first": "C. Y.",
                    "initial": "C.Y.",
                    "last": "Chan"
                },
                {
                    "first": "I. S.F.",
                    "initial": "I.S.F.",
                    "last": "Chan"
                },
                {
                    "first": "W. W.B.",
                    "initial": "W.W.B.",
                    "last": "Wang"
                },
                {
                    "first": "P. W.",
                    "initial": "P.W.",
                    "last": "Annunziato"
                },
                {
                    "first": "J. L.",
                    "initial": "J.L.",
                    "last": "Silber"
                }
            ],
            "doi": "10.1056/NEJMoa051016",
            "firstpage": "2271",
            "issn": "00284793",
            "lastpage": "2365",
            "pmid": "15930418",
            "pub_year": 2005,
            "title": "A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults",
            "volume": "352"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "Jos\u00e9 M.",
                    "initial": "J.M.",
                    "last": "Bayas"
                },
                {
                    "first": "Harry",
                    "initial": "H.",
                    "last": "Collins"
                },
                {
                    "first": "Maria Luisa Rodriguez",
                    "initial": "M.L.R.",
                    "last": "De La Pinta"
                },
                {
                    "first": "Edouard",
                    "initial": "E.",
                    "last": "Ledent"
                },
                {
                    "first": "Johann F.",
                    "initial": "J.F.",
                    "last": "Mols"
                },
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                }
            ],
            "doi": "10.1093/infdis/jit365",
            "firstpage": "1953",
            "issn": "00221899",
            "lastpage": "1961",
            "pmid": "23904292",
            "pub_year": 2013,
            "title": "Safety and immunogenicity of an ASO1 -adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults \u226550 years of age",
            "volume": "208"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "Jan",
                    "initial": "J.",
                    "last": "Smetana"
                },
                {
                    "first": "Karlis",
                    "initial": "K.",
                    "last": "Pauksens"
                },
                {
                    "first": "Lars",
                    "initial": "L.",
                    "last": "Rombo"
                },
                {
                    "first": "J. Anneke R.",
                    "initial": "J.A.R.",
                    "last": "Van den Hoek"
                },
                {
                    "first": "Jan H.",
                    "initial": "J.H.",
                    "last": "Richardus"
                },
                {
                    "first": "Georg",
                    "initial": "G.",
                    "last": "Plassmann"
                },
                {
                    "first": "Tino F.",
                    "initial": "T.F.",
                    "last": "Schwarz"
                },
                {
                    "first": "Edouard",
                    "initial": "E.",
                    "last": "Ledent"
                },
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.01.019",
            "firstpage": "1745",
            "issn": "0264410X",
            "lastpage": "1753",
            "pmid": "24508036",
            "pub_year": 2014,
            "title": "Safety and immunogenicity of three different formulations of an adjuvanted varicella-zoster virus subunit candidate vaccine in older adults: A phase II, randomized, controlled study",
            "volume": "32"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "Karlis",
                    "initial": "K.",
                    "last": "Pauksens"
                },
                {
                    "first": "Lars",
                    "initial": "L.",
                    "last": "Rombo"
                },
                {
                    "first": "Gini",
                    "initial": "G.",
                    "last": "van Rijckevorsel"
                },
                {
                    "first": "Jan H.",
                    "initial": "J.H.",
                    "last": "Richardus"
                },
                {
                    "first": "Georg",
                    "initial": "G.",
                    "last": "Plassmann"
                },
                {
                    "first": "Tino F.",
                    "initial": "T.F.",
                    "last": "Schwarz"
                },
                {
                    "first": "Gr\u00e9gory",
                    "initial": "G.",
                    "last": "Catteau"
                },
                {
                    "first": "Himal",
                    "initial": "H.",
                    "last": "Lal"
                },
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.09.073",
            "firstpage": "863",
            "issn": "0264410X",
            "lastpage": "868",
            "pmid": "26432913",
            "pub_year": 2016,
            "title": "Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults",
            "volume": "34"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Himal",
                    "initial": "H.",
                    "last": "Lal"
                },
                {
                    "first": "Anthony L.",
                    "initial": "A.L.",
                    "last": "Cunningham"
                },
                {
                    "first": "Olivier",
                    "initial": "O.",
                    "last": "Godeaux"
                },
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "Diez-Domingo"
                },
                {
                    "first": "Shinn Jang",
                    "initial": "S.J.",
                    "last": "Hwang"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "Janet E.",
                    "initial": "J.E.",
                    "last": "McElhaney"
                },
                {
                    "first": "Airi",
                    "initial": "A.",
                    "last": "Poder"
                },
                {
                    "first": "Joan",
                    "initial": "J.",
                    "last": "Puig-Barber\u00e0"
                },
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Daisuke",
                    "initial": "D.",
                    "last": "Watanabe"
                },
                {
                    "first": "Lily",
                    "initial": "L.",
                    "last": "Weckx"
                },
                {
                    "first": "Toufik",
                    "initial": "T.",
                    "last": "Zahaf"
                },
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1056/NEJMoa1501184",
            "firstpage": "2087",
            "issn": "00284793",
            "lastpage": "2096",
            "pmid": "25916341",
            "pub_year": 2015,
            "title": "Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults",
            "volume": "372"
        },
        "b0045": {
            "authors": [
                {
                    "first": "A. L.",
                    "initial": "A.L.",
                    "last": "Cunningham"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Lal"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Kovac"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Chlibek"
                },
                {
                    "first": "S. J.",
                    "initial": "S.J.",
                    "last": "Hwang"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "D\u00edez-Domingo"
                },
                {
                    "first": "O.",
                    "initial": "O.",
                    "last": "Godeaux"
                },
                {
                    "first": "M. J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "J. E.",
                    "initial": "J.E.",
                    "last": "McElhaney"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Puig-Barber\u00e0"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Vanden Abeele"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Watanabe"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Zahaf"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Ahonen"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Athan"
                },
                {
                    "first": "J. F.",
                    "initial": "J.F.",
                    "last": "Barba-Gomez"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Campora"
                },
                {
                    "first": "F.",
                    "initial": "F.",
                    "last": "De Looze"
                },
                {
                    "first": "H. J.",
                    "initial": "H.J.",
                    "last": "Downey"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Ghesquiere"
                },
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Gorfinkel"
                },
                {
                    "first": "T.",
                    "initial": "T.",
                    "last": "Korhonen"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Leung"
                },
                {
                    "first": "S. A.",
                    "initial": "S.A.",
                    "last": "McNeil"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Oostvogels"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Rombo"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Smetana"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Weckx"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Yeo"
                },
                {
                    "first": "T. C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                }
            ],
            "doi": "10.1056/NEJMoa1603800",
            "firstpage": "1019",
            "issn": "00284793",
            "lastpage": "1032",
            "pmid": "27626517",
            "pub_year": 2016,
            "title": "Efficacy of the herpes zoster subunit vaccine in adults 70 years of age or older",
            "volume": "375"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Adriana",
                    "initial": "A.",
                    "last": "Weinberg"
                },
                {
                    "first": "Jane H.",
                    "initial": "J.H.",
                    "last": "Zhang"
                },
                {
                    "first": "Michael N.",
                    "initial": "M.N.",
                    "last": "Oxman"
                },
                {
                    "first": "Gary R.",
                    "initial": "G.R.",
                    "last": "Johnson"
                },
                {
                    "first": "Anthony R.",
                    "initial": "A.R.",
                    "last": "Hayward"
                },
                {
                    "first": "Michael J.",
                    "initial": "M.J.",
                    "last": "Caulfield"
                },
                {
                    "first": "Michael R.",
                    "initial": "M.R.",
                    "last": "Irwin"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Clair"
                },
                {
                    "first": "Jeffrey G.",
                    "initial": "J.G.",
                    "last": "Smith"
                },
                {
                    "first": "Harold",
                    "initial": "H.",
                    "last": "Stanley"
                },
                {
                    "first": "Rocio D.",
                    "initial": "R.D.",
                    "last": "Marchese"
                },
                {
                    "first": "Ruth",
                    "initial": "R.",
                    "last": "Harbecke"
                },
                {
                    "first": "Heather M.",
                    "initial": "H.M.",
                    "last": "Williams"
                },
                {
                    "first": "Ivan S.F.",
                    "initial": "I.S.F.",
                    "last": "Chan"
                },
                {
                    "first": "Robert D.",
                    "initial": "R.D.",
                    "last": "Arbeit"
                },
                {
                    "first": "Anne A.",
                    "initial": "A.A.",
                    "last": "Gershon"
                },
                {
                    "first": "Florian",
                    "initial": "F.",
                    "last": "Sch\u00f6del"
                },
                {
                    "first": "Vicki A.",
                    "initial": "V.A.",
                    "last": "Morrison"
                },
                {
                    "first": "Carol A.",
                    "initial": "C.A.",
                    "last": "Kauffman"
                },
                {
                    "first": "Steve E.",
                    "initial": "S.E.",
                    "last": "Straus"
                },
                {
                    "first": "Kenneth E.",
                    "initial": "K.E.",
                    "last": "Schmader"
                },
                {
                    "first": "Larry E.",
                    "initial": "L.E.",
                    "last": "Davis"
                },
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                }
            ],
            "doi": "10.1086/605611",
            "firstpage": "1068",
            "issn": "00221899",
            "lastpage": "1077",
            "pmid": "19712037",
            "pub_year": 2009,
            "title": "Varicella-zoster vrrus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine",
            "volume": "200"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Myron J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "M. N.",
                    "initial": "M.N.",
                    "last": "Oxman"
                },
                {
                    "first": "J. H.",
                    "initial": "J.H.",
                    "last": "Zhang"
                },
                {
                    "first": "G. R.",
                    "initial": "G.R.",
                    "last": "Johnson"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Stanley"
                },
                {
                    "first": "A. R.",
                    "initial": "A.R.",
                    "last": "Hayward"
                },
                {
                    "first": "M. J.",
                    "initial": "M.J.",
                    "last": "Caulfield"
                },
                {
                    "first": "M. R.",
                    "initial": "M.R.",
                    "last": "Irwin"
                },
                {
                    "first": "J. G.",
                    "initial": "J.G.",
                    "last": "Smith"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Clair"
                },
                {
                    "first": "I. S.F.",
                    "initial": "I.S.F.",
                    "last": "Chan"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Williams"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Harbecke"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Marchese"
                },
                {
                    "first": "S. E.",
                    "initial": "S.E.",
                    "last": "Straus"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Gershon"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Weinberg"
                },
                {
                    "first": "Michael N.",
                    "initial": "M.N.",
                    "last": "Oxman"
                },
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Arbeit"
                },
                {
                    "first": "Patricia",
                    "initial": "P.",
                    "last": "Barry"
                },
                {
                    "first": "Chris",
                    "initial": "C.",
                    "last": "Beisel"
                },
                {
                    "first": "Kathy D.",
                    "initial": "K.D.",
                    "last": "Boardman"
                },
                {
                    "first": "Cindy L.",
                    "initial": "C.L.",
                    "last": "Colling"
                },
                {
                    "first": "Larry",
                    "initial": "L.",
                    "last": "Davis"
                },
                {
                    "first": "Lawrence",
                    "initial": "L.",
                    "last": "Gelb"
                },
                {
                    "first": "Anne A.",
                    "initial": "A.A.",
                    "last": "Gershon"
                },
                {
                    "first": "Anthony R.",
                    "initial": "A.R.",
                    "last": "Hayward"
                },
                {
                    "first": "Michael R.",
                    "initial": "M.R.",
                    "last": "Irwin"
                },
                {
                    "first": "Gary R.",
                    "initial": "G.R.",
                    "last": "Johnson"
                },
                {
                    "first": "Peter N.",
                    "initial": "P.N.",
                    "last": "Peduzzi"
                },
                {
                    "first": "Kenneth",
                    "initial": "K.",
                    "last": "Schmader"
                },
                {
                    "first": "Michael S.",
                    "initial": "M.S.",
                    "last": "Simberkoff"
                },
                {
                    "first": "Stephen E.",
                    "initial": "S.E.",
                    "last": "Straus"
                },
                {
                    "first": "Adriana",
                    "initial": "A.",
                    "last": "Weinberg"
                },
                {
                    "first": "Heather M.",
                    "initial": "H.M.",
                    "last": "Williams"
                },
                {
                    "first": "Jeffrey L.",
                    "initial": "J.L.",
                    "last": "Silber"
                },
                {
                    "first": "Paula",
                    "initial": "P.",
                    "last": "Annunziato"
                },
                {
                    "first": "Christina Y.",
                    "initial": "C.Y.",
                    "last": "Chan"
                },
                {
                    "first": "Ivan S.F.",
                    "initial": "I.S.F.",
                    "last": "Chan"
                },
                {
                    "first": "L. E.",
                    "initial": "L.E.",
                    "last": "Davis"
                },
                {
                    "first": "C. A.",
                    "initial": "C.A.",
                    "last": "Kauffman"
                },
                {
                    "first": "S. K.",
                    "initial": "S.K.",
                    "last": "Keay"
                },
                {
                    "first": "A. R.",
                    "initial": "A.R.",
                    "last": "Marques"
                },
                {
                    "first": "N. E.",
                    "initial": "N.E.",
                    "last": "Soto"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Brunell"
                },
                {
                    "first": "J. W.",
                    "initial": "J.W.",
                    "last": "Gnann"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Serrao"
                },
                {
                    "first": "D. J.",
                    "initial": "D.J.",
                    "last": "Cotton"
                },
                {
                    "first": "R. P.",
                    "initial": "R.P.",
                    "last": "Goodman"
                },
                {
                    "first": "R. D.",
                    "initial": "R.D.",
                    "last": "Arbeit"
                },
                {
                    "first": "C. T.",
                    "initial": "C.T.",
                    "last": "Pachucki"
                },
                {
                    "first": "M. J.",
                    "initial": "M.J.",
                    "last": "Levin"
                },
                {
                    "first": "K. E.",
                    "initial": "K.E.",
                    "last": "Schmader"
                },
                {
                    "first": "W. A.",
                    "initial": "W.A.",
                    "last": "Keitel"
                },
                {
                    "first": "R. N.",
                    "initial": "R.N.",
                    "last": "Greenberg"
                },
                {
                    "first": "V. A.",
                    "initial": "V.A.",
                    "last": "Morrison"
                },
                {
                    "first": "P. F.",
                    "initial": "P.F.",
                    "last": "Wright"
                },
                {
                    "first": "M. R.",
                    "initial": "M.R.",
                    "last": "Griffin"
                },
                {
                    "first": "M. S.",
                    "initial": "M.S.",
                    "last": "Simberkoff"
                },
                {
                    "first": "S. S.",
                    "initial": "S.S.",
                    "last": "Yeh"
                },
                {
                    "first": "Z.",
                    "initial": "Z.",
                    "last": "Lobo"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Holodniy"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Loutit"
                },
                {
                    "first": "R. F.",
                    "initial": "R.F.",
                    "last": "Betts"
                },
                {
                    "first": "L. D.",
                    "initial": "L.D.",
                    "last": "Gelb"
                },
                {
                    "first": "G. E.",
                    "initial": "G.E.",
                    "last": "Crawford"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Guatelli"
                },
                {
                    "first": "P. A.",
                    "initial": "P.A.",
                    "last": "Brooks"
                },
                {
                    "first": "K. M.",
                    "initial": "K.M.",
                    "last": "Neuzil"
                },
                {
                    "first": "J. F.",
                    "initial": "J.F.",
                    "last": "Toney"
                }
            ],
            "doi": "10.1086/528696",
            "firstpage": "825",
            "issn": "00221899",
            "lastpage": "835",
            "pmid": "18419349",
            "pub_year": 2008,
            "title": "Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine",
            "volume": "197"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Peter B.",
                    "initial": "P.B.",
                    "last": "Gilbert"
                },
                {
                    "first": "Erin E.",
                    "initial": "E.E.",
                    "last": "Gabriel"
                },
                {
                    "first": "Xiaopeng",
                    "initial": "X.",
                    "last": "Miao"
                },
                {
                    "first": "Xiaoming",
                    "initial": "X.",
                    "last": "Li"
                },
                {
                    "first": "Shu Chih",
                    "initial": "S.C.",
                    "last": "Su"
                },
                {
                    "first": "Janie",
                    "initial": "J.",
                    "last": "Parrino"
                },
                {
                    "first": "Ivan S.F.",
                    "initial": "I.S.F.",
                    "last": "Chan"
                }
            ],
            "doi": "10.1093/infdis/jiu279",
            "firstpage": "1573",
            "issn": "00221899",
            "lastpage": "1581",
            "pmid": "24823623",
            "pub_year": 2014,
            "title": "Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked Immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve",
            "volume": "210"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Himal",
                    "initial": "H.",
                    "last": "Lal"
                },
                {
                    "first": "Toufik",
                    "initial": "T.",
                    "last": "Zahaf"
                },
                {
                    "first": "Thomas C.",
                    "initial": "T.C.",
                    "last": "Heineman"
                }
            ],
            "doi": "10.4161/hv.24269",
            "firstpage": "1425",
            "issn": "21645515",
            "lastpage": "1429",
            "pmid": "23584252",
            "pub_year": 2013,
            "title": "Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su): A phase-I, open-label study in Japanese adults",
            "volume": "9"
        }
    },
    "body_text": [
        {
            "endOffset": 16982,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 16981,
                    "startOffset": 16978
                }
            },
            "secId": "s0005",
            "sentence": "Half of all HZ cases occur in people over 60 YOA, and it is estimated that individuals who live to be 85 years old have a 50% chance of having HZ during their lifetime [3].",
            "startOffset": 16810,
            "title": "Introduction"
        },
        {
            "endOffset": 26868,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Distribution among groups and reasons for exclusion are presented in Fig. 1.",
            "startOffset": 26792,
            "title": "Demographics"
        },
        {
            "endOffset": 26965,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "The mean age at dose 1 was 64.5, 64.0 and 64.1 years in Gr 0\u20132, Gr 0\u20136 and Gr 0\u201312, respectively.",
            "startOffset": 26868,
            "title": "Demographics"
        },
        {
            "endOffset": 32986,
            "parents": [],
            "secId": "s0080",
            "sentence": "HZ/su-induced humoral immune responses were non-inferior when the interval between the doses was increased from 2 to 6 months in adults \u226550 YOA, which may allow flexibility in terms of timing of the second dose.",
            "startOffset": 32775,
            "title": "Discussion"
        },
        {
            "endOffset": 35625,
            "parents": [],
            "secId": "s0090",
            "sentence": "Immunogenicity and Safety of 2 Doses of an Investigational Herpes Zoster Subunit Vaccine Administered 2, 6 or 12 Months Apart in Adults 50 Years and Older: Results of a Phase III, Randomized, Open-label, Multicenter Trial.",
            "startOffset": 35403,
            "title": "Meeting"
        },
        {
            "endOffset": 28315,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "One month post-dose 2, at least a 35.8-fold increase in anti-gE GMCs compared to baseline was seen (Gr 0\u20132: 41.1; Gr 0\u20136: 35.8; Gr 0\u201312: 36.3).",
            "startOffset": 28172,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 28565,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "The seropositivity rate at pre-vaccination was high (>99%) and all participants remained seropositive at 12 months post-dose 2.",
            "startOffset": 28438,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 18023,
            "parents": [],
            "secId": "s0005",
            "sentence": "For both the vaccine recipients and healthcare providers, the ability to increase the interval between doses provides more flexibility to complete the 2-dose schedule.",
            "startOffset": 17856,
            "title": "Introduction"
        },
        {
            "endOffset": 29564,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Myalgia was reported with incidences of 52.9% in Gr 0\u20132, 47.9% in Gr 0\u20136, and 55.2% in Gr 0\u201312.",
            "startOffset": 29469,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 34913,
            "parents": [],
            "secId": "s0085",
            "sentence": "Two doses of HZ/su elicited robust anti-gE immune responses in adults \u226550 YOA with all 3 schedules.",
            "startOffset": 34814,
            "title": "Conclusions"
        },
        {
            "endOffset": 25870,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0045",
                    "title": "Statistical analyses"
                }
            ],
            "secId": "s0050",
            "sentence": "Seropositivity rates, GMCs and VRRs with exact 95% CIs were computed at each time point.",
            "startOffset": 25782,
            "title": "Immunogenicity analyses"
        },
        {
            "endOffset": 32006,
            "parents": [],
            "secId": "s0080",
            "sentence": "Despite performing all logistical and clinical due diligence, no explanation for the low anti-gE antibody levels post-vaccination of these 9 participants in Gr 0\u201312 could be identified.",
            "startOffset": 31821,
            "title": "Discussion"
        },
        {
            "endOffset": 22172,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Blood samples for the assessment of the humoral immune responses to HZ/su (anti-gE antibody concentrations) were collected at baseline, 1 month post-dose 2 and for persistence at 12 months post-dose 2 (Fig. S1).",
            "startOffset": 21961,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 17536,
            "parents": [],
            "secId": "s0005",
            "sentence": "In recent phase III clinical trials, the administration of 2 doses of HZ/su 2 months apart, significantly reduced the risk of HZ in adults \u226550 (ZOE-50) and \u226570 (ZOE-70) YOA.",
            "startOffset": 17363,
            "title": "Introduction"
        },
        {
            "endOffset": 27680,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "The adjusted GMC ratios were 1.16 (97.5% CI: 0.98; 1.39) in the Gr 0\u20136 group (Gr 0\u20132 over Gr 0\u20136) and 1.19 (97.5% CI: 0.93; 1.53) in the Gr 0\u201312 group (Gr 0\u20132 over Gr 0\u201312).",
            "startOffset": 27507,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 30937,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "No pIMDs or suspected HZ cases were reported during the study.",
            "startOffset": 30875,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 25782,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0045",
                    "title": "Statistical analyses"
                }
            ],
            "secId": "s0050",
            "sentence": "The pre-vaccination log-transformed antibody concentration was included as continuous covariate and the ANCOVA model included the study group and age strata as fixed effects.",
            "startOffset": 25608,
            "title": "Immunogenicity analyses"
        },
        {
            "endOffset": 35741,
            "parents": [],
            "secId": "s0095",
            "sentence": "HL, AP, LC and TCH collected the data.",
            "startOffset": 35703,
            "title": "Author\u2019s contribution"
        },
        {
            "endOffset": 18663,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Female participants had to be of non-child bearing potential or have a negative pregnancy test on the day of vaccination and meet the contraceptive requirements as outlined in the protocol.",
            "startOffset": 18474,
            "title": "Study design and participants"
        },
        {
            "endOffset": 32516,
            "parents": [],
            "secId": "s0080",
            "sentence": "In retrospect, if post-dose 1 humoral response data at 1\u20132 months following vaccination was available, it would have allowed assessment of immunogenicity at a similar time point after dose 1 in all three groups thus allowing us to assess if these 9 participants in Gr 0\u201312 had lower responses to vaccination to begin with, or if the lower responses are due to increasing the interval between 2 doses.",
            "startOffset": 32116,
            "title": "Discussion"
        },
        {
            "endOffset": 24921,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "Assuming 15% non-evaluable participants, a total of 354 adults were to be enrolled (118 adults per study group).",
            "startOffset": 24809,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 26626,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Eight participants withdrew from the study: 4 participants due to an SAE, 3 participants were lost to follow-up and 1 withdrew consent.",
            "startOffset": 26491,
            "title": "Demographics"
        },
        {
            "endOffset": 21342,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Non-inferiority was established if the upper limit of the 97.5% CI for the anti-gE ELISA GMC ratio (Gr 0\u20132 over Gr 0\u20136) at 1 month post-dose 2 was <1.5.",
            "startOffset": 21190,
            "title": "Outcomes"
        },
        {
            "endOffset": 32775,
            "parents": [],
            "secId": "s0080",
            "sentence": "Assessing gE-specific cell-mediated-immune responses in the study would have provided additional information that may have been helpful in understanding these results.",
            "startOffset": 32608,
            "title": "Discussion"
        },
        {
            "endOffset": 17127,
            "parents": [],
            "secId": "s0005",
            "sentence": "In phase II studies, GSK\u2019s HZ subunit vaccine (HZ/su) was shown to be immunogenic when administered to adults \u226550 YOA as 2 doses, 2 months apart.",
            "startOffset": 16982,
            "title": "Introduction"
        },
        {
            "endOffset": 33730,
            "parents": [],
            "secId": "s0080",
            "sentence": "In this study, 1 month post-dose 2, at least a 35.8-fold-increase in anti-gE GMCs was seen with all schedules.",
            "startOffset": 33620,
            "title": "Discussion"
        },
        {
            "endOffset": 31820,
            "parents": [],
            "secId": "s0080",
            "sentence": "Similar subjects with markedly lower anti gE antibody levels post vaccination were not observed in other groups.",
            "startOffset": 31708,
            "title": "Discussion"
        },
        {
            "endOffset": 34059,
            "parents": [],
            "secId": "s0080",
            "sentence": "This would have required a larger sample size.",
            "startOffset": 34013,
            "title": "Discussion"
        },
        {
            "endOffset": 21189,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Once met, this would allow analysis of the second co-primary objective: to assess the non-inferiority of anti-gE ELISA responses (based on geometric mean concentrations [GMCs]) for the Gr 0\u20136 study group.",
            "startOffset": 20985,
            "title": "Outcomes"
        },
        {
            "endOffset": 28726,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "In Gr 0\u201312, 9 individuals were identified, across all three age groups, who responded to 2 doses of vaccine (anti-gE GMCs) substantially below the mean (Fig. 3).",
            "startOffset": 28565,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 23246,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The intensity of all AEs was graded on a scale from 1 to 3.",
            "startOffset": 23187,
            "title": "Safety and reactogenicity assessment"
        },
        {
            "endOffset": 31301,
            "parents": [],
            "secId": "s0080",
            "sentence": "In adults \u226550 YOA, the non-inferiority of the 0, 6-month HZ/su 2-dose vaccination schedule to the standard 0, 2-month schedule in terms of anti-gE humoral immune responses 1 month post-dose 2 was demonstrated.",
            "startOffset": 31092,
            "title": "Discussion"
        },
        {
            "endOffset": 31707,
            "parents": [],
            "secId": "s0080",
            "sentence": "The fact that the GMC non-inferiority criterion was not met for the 0, 12-month schedule may have been due to a small number of participants with markedly lower anti-gE antibody levels post-vaccination.",
            "startOffset": 31505,
            "title": "Discussion"
        },
        {
            "endOffset": 25382,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0045",
                    "title": "Statistical analyses"
                }
            ],
            "secId": "s0050",
            "sentence": "If, in any vaccine group, the percentage of vaccinated participants with serological results excluded from the ATP cohort for immunogenicity was 5% or more, a second analysis based on the TVC was to be performed to complement the ATP analysis.",
            "startOffset": 25139,
            "title": "Immunogenicity analyses"
        },
        {
            "endOffset": 26791,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "The ATP cohort for immunogenicity included 343 adults at 1 month post-dose 2, and the ATP cohort for persistence included 342 participants at 12 months post-dose 2.",
            "startOffset": 26627,
            "title": "Demographics"
        },
        {
            "endOffset": 34493,
            "parents": [],
            "secId": "s0080",
            "sentence": "HZ/su had a clinically acceptable safety profile in this population, with no SAEs assessed by the investigators as vaccine-related.",
            "startOffset": 34362,
            "title": "Discussion"
        },
        {
            "endOffset": 35402,
            "parents": [],
            "secId": "s0090",
            "sentence": "Airi Poder, Brecht Geeraerts, Himal Lal, Lidia Oostvogels, Carline Vanden Abeele, Thomas Heineman.",
            "startOffset": 35304,
            "title": "Meeting"
        },
        {
            "endOffset": 24808,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "In order to have at least 90% power to achieve the co-primary objectives for at least 1 candidate schedule (0, 6-month or 0, 12-month), the sample size had been derived by ensuring beta less than 1% and 9%, respectively (Bonferroni adjustment of beta).",
            "startOffset": 24556,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 36106,
            "parents": [],
            "secId": "s0095",
            "sentence": "GSK takes a commitment to convey a message in a way that would be easily understandable by Health Care Professionals (Supplementary Material).",
            "startOffset": 35964,
            "title": "Author\u2019s contribution"
        },
        {
            "endOffset": 21933,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Secondary objectives included the characterization of anti-gE humoral immune responses for all study groups at all sampling time points and the evaluation of safety and reactogenicity following administration of HZ/su.",
            "startOffset": 21715,
            "title": "Outcomes"
        },
        {
            "endOffset": 18188,
            "parents": [],
            "secId": "s0005",
            "sentence": "Therefore, the current study assessed the immunogenicity, reactogenicity and safety of 2 doses of HZ/su administered to adults \u226550 YOA at 6- and 12-month intervals.",
            "startOffset": 18024,
            "title": "Introduction"
        },
        {
            "endOffset": 21517,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Similarly, the success criterion for the 0, 12-month schedule was met if the LL of the 97.5% CI of the VRR for anti-gE antibody concentrations at 1 month post-dose 2 was \u226560%.",
            "startOffset": 21342,
            "title": "Outcomes"
        },
        {
            "endOffset": 27069,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "Across groups, the majority of the participants were females of Caucasian/European heritage (Table S1).",
            "startOffset": 26966,
            "title": "Demographics"
        },
        {
            "endOffset": 23664,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "All solicited local reactions were considered causally related to vaccination.",
            "startOffset": 23586,
            "title": "Safety and reactogenicity assessment"
        },
        {
            "endOffset": 22411,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Participants with anti-gE antibody concentrations \u226597 mIU/mL were considered seropositive.",
            "startOffset": 22321,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 24555,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "100 evaluable participants per each of the three groups were needed to demonstrate the first and second co-primary objectives with a power of at least 99% and 91% respectively.",
            "startOffset": 24379,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 35164,
            "parents": [],
            "secId": "s0085",
            "sentence": "Non-inferiority in terms of anti-gE humoral immune responses 1 month post-dose 2 was not demonstrated for the 0, 12-month schedule.",
            "startOffset": 35033,
            "title": "Conclusions"
        },
        {
            "endOffset": 18473,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Adults \u226550 YOA were eligible for inclusion in the study.",
            "startOffset": 18417,
            "title": "Study design and participants"
        },
        {
            "endOffset": 35245,
            "parents": [],
            "secId": "s0085",
            "sentence": "HZ/su exhibited a clinically acceptable safety profile for all dosing intervals.",
            "startOffset": 35165,
            "title": "Conclusions"
        },
        {
            "endOffset": 17233,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 17232,
                    "startOffset": 17227
                },
                "b0030": {
                    "endOffset": 17232,
                    "startOffset": 17227
                }
            },
            "secId": "s0005",
            "sentence": "Immune responses were higher after the second HZ/su dose than after the first dose in these trials [5,6].",
            "startOffset": 17128,
            "title": "Introduction"
        },
        {
            "endOffset": 22765,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The VRR for anti-gE was defined as the percentage of study participants who had a \u22654-fold increase in the post-dose 2 anti-gE antibody concentration as compared to the pre-vaccination concentration (for initially seropositive participants) or as compared to the anti-gE antibody cut-off value for seropositivity (for initially seronegative participants).",
            "startOffset": 22411,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 25138,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0045",
                    "title": "Statistical analyses"
                }
            ],
            "secId": "s0050",
            "sentence": "The analysis was based on the adapted ATP cohort for immunogenicity/persistence, meaning that for each time point, the corresponding ATP cohort for immunogenicity/persistence has been used.",
            "startOffset": 24949,
            "title": "Immunogenicity analyses"
        },
        {
            "endOffset": 23962,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Suspected HZ cases, medically attended visits, serious AEs (SAEs) and potential immune-mediated diseases (pIMDs) were recorded from the first study vaccine administration up to study end (12 months post-dose 2, for each participant).",
            "startOffset": 23729,
            "title": "Safety and reactogenicity assessment"
        },
        {
            "endOffset": 17856,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 17855,
                    "startOffset": 17850
                },
                "b0030": {
                    "endOffset": 17855,
                    "startOffset": 17850
                },
                "b0035": {
                    "endOffset": 17855,
                    "startOffset": 17850
                },
                "b0040": {
                    "endOffset": 17855,
                    "startOffset": 17850
                }
            },
            "secId": "s0005",
            "sentence": "In all completed phase II and phase III studies, HZ/su was well tolerated and had a clinically acceptable safety profile [5\u20138].",
            "startOffset": 17729,
            "title": "Introduction"
        },
        {
            "endOffset": 20525,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "The enrollment was age-stratified to ensure a balanced distribution of participants across three age strata (50\u201359 years, 60\u201369 years and \u226570 years).",
            "startOffset": 20376,
            "title": "Randomization and masking"
        },
        {
            "endOffset": 29673,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Headache was reported by 39.5%, 39.5% and 45.7% of participants in Gr 0\u20132, Gr 0\u20136 and Gr 0\u201312, respectively.",
            "startOffset": 29565,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 21715,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "In that case the next second co-primary objective, non-inferiority based on the GMC ratio, could also be assessed for the 0, 12-month schedule; assessment was done in the same manner as for Gr 0\u20136.",
            "startOffset": 21518,
            "title": "Outcomes"
        },
        {
            "endOffset": 34631,
            "parents": [],
            "secId": "s0080",
            "sentence": "The higher number of SAEs in the Gr 0\u20136 and Gr 0\u201312 groups, compared to Gr 0\u20132, was due to the longer follow-up periods for these groups.",
            "startOffset": 34494,
            "title": "Discussion"
        },
        {
            "endOffset": 24104,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The total vaccinated cohort (TVC) included all enrolled participants with at least 1 documented vaccine administration.",
            "startOffset": 23985,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 33188,
            "parents": [],
            "secId": "s0080",
            "sentence": "A benefit of a flexible dosing schedule might be improved 2-dose compliance, in part by allowing vaccine administration at routine physician visits rather than requiring a designated vaccination visit.",
            "startOffset": 32987,
            "title": "Discussion"
        },
        {
            "endOffset": 32607,
            "parents": [],
            "secId": "s0080",
            "sentence": "Other unknown factors may have played a role in these participants\u2019 low responses as well.",
            "startOffset": 32517,
            "title": "Discussion"
        },
        {
            "endOffset": 35032,
            "parents": [],
            "secId": "s0085",
            "sentence": "Immune responses to HZ/su administered at months 0 and 6 were non-inferior to those elicited by a 0, 2-month schedule.",
            "startOffset": 34914,
            "title": "Conclusions"
        },
        {
            "endOffset": 16809,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 16808,
                    "startOffset": 16803
                },
                "b0020": {
                    "endOffset": 16808,
                    "startOffset": 16803
                }
            },
            "secId": "s0005",
            "sentence": "The incidence of HZ at 50\u201359 years of age (YOA) is about 5 cases per 1000 persons per year, and it increases to 10 cases per 1000 persons per year in people \u226560 YOA [3,4].",
            "startOffset": 16638,
            "title": "Introduction"
        },
        {
            "endOffset": 16457,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 16456,
                    "startOffset": 16451
                },
                "b0010": {
                    "endOffset": 16456,
                    "startOffset": 16451
                }
            },
            "secId": "s0005",
            "sentence": "Herpes zoster (HZ; shingles) is caused by reactivation of latent varicella-zoster virus (VZV) and typically manifests as a localized, dermatomal rash [1,2].",
            "startOffset": 16301,
            "title": "Introduction"
        },
        {
            "endOffset": 19516,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study was conducted in accordance with the Declaration of Helsinki and the principles of Good Clinical Practice.",
            "startOffset": 19400,
            "title": "Study design and participants"
        },
        {
            "endOffset": 30419,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "From first vaccination until study end, SAEs were reported by 5 (4.2%) participants in Gr 0\u20132, 9 (7.6%) in Gr 0\u20136 and 12 (10.3%) in Gr 0\u201312.",
            "startOffset": 30279,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 33375,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 33296,
                    "startOffset": 33289
                },
                "b0055": {
                    "endOffset": 33296,
                    "startOffset": 33289
                }
            },
            "secId": "s0080",
            "sentence": "While humoral immune responses are not thought to be primarily responsible for protection against HZ [10,11], the immunologic mechanisms underlying protection have not been fully defined.",
            "startOffset": 33188,
            "title": "Discussion"
        },
        {
            "endOffset": 27940,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "HZ/su elicited robust anti-gE humoral immune responses in all groups.",
            "startOffset": 27871,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 23187,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "All events were reported by the study participants on diary cards, which they had to return after completion.",
            "startOffset": 23078,
            "title": "Safety and reactogenicity assessment"
        },
        {
            "endOffset": 29468,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Fatigue was reported by 45.4% of study participants in Gr 0\u20132, 52.9% in Gr 0\u20136, and 61.2% in Gr 0\u201312.",
            "startOffset": 29367,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 35651,
            "parents": [],
            "secId": "s0090",
            "sentence": "IDWeek 2016 (poster 753).",
            "startOffset": 35626,
            "title": "Meeting"
        },
        {
            "endOffset": 30652,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Two fatal events were reported during the study, 1 participant in Gr 0\u20132 due to intracerebral haemorrhage, and 1 participant in Gr 0\u201312 due to cardiovascular disorder; neither assessed by the investigators as related to vaccination.",
            "startOffset": 30420,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 26490,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0065",
            "sentence": "354 adults were enrolled in the study, and 346 completed the study.",
            "startOffset": 26423,
            "title": "Demographics"
        },
        {
            "endOffset": 27507,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "As these values were above 60%, the co-primary objective to evaluate the VRRs for anti-gE humoral immune responses at this time point was met for both schedules.",
            "startOffset": 27346,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 25949,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0045",
                    "title": "Statistical analyses"
                }
            ],
            "secId": "s0055",
            "sentence": "The primary analysis for safety was carried out on the TVC.",
            "startOffset": 25890,
            "title": "Safety analyses"
        },
        {
            "endOffset": 30279,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "The most frequently reported unsolicited events related to vaccination were injection site pruritus in Gr 0\u20132 (by 2.5% of participants), erythema (2.5%) in Gr 0\u20136 and injection site pruritus and arthralgia (1.7%) in Gr 0\u201312.",
            "startOffset": 30055,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 27871,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Non-inferiority of the anti-gE humoral immune response 1 month post-dose 2 compared to the 0, 2-month schedule was demonstrated for the 0, 6-month schedule, but not the 0, 12-month schedule.",
            "startOffset": 27681,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 26198,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0045",
                    "title": "Statistical analyses"
                }
            ],
            "secId": "s0055",
            "sentence": "The percentage of participants reporting solicited local and general symptoms and unsolicited AEs, as well as grade 3 symptoms, AEs with causal relationship to vaccination, or medically attended AEs, with exact 95% CIs, were computed for each group.",
            "startOffset": 25949,
            "title": "Safety analyses"
        },
        {
            "endOffset": 26400,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0045",
                    "title": "Statistical analyses"
                }
            ],
            "secId": "s0055",
            "sentence": "All statistical analyses were performed using the SAS version 9.3 on windows SDD 4.0.",
            "startOffset": 26315,
            "title": "Safety analyses"
        },
        {
            "endOffset": 25607,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0045",
                    "title": "Statistical analyses"
                }
            ],
            "secId": "s0050",
            "sentence": "For the co-primary objectives, VRRs with exact 97.5% CIs were computed and the 97.5% CIs of the group GMC ratios were evaluated using an analysis of covariance (ANCOVA) model on the log10-transformation of the concentrations.",
            "startOffset": 25382,
            "title": "Immunogenicity analyses"
        },
        {
            "endOffset": 19107,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Adults were excluded from participation in the study if they had taken any investigational or non-registered product other than the study vaccine, were administered or planned to receive a live or non-replicating vaccine for the protocol-specified time period, had a history of HZ, received previous vaccination against varicella or HZ, or had a history of reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.",
            "startOffset": 18664,
            "title": "Study design and participants"
        },
        {
            "endOffset": 35702,
            "parents": [],
            "secId": "s0095",
            "sentence": "HL and TCH designed the study.",
            "startOffset": 35672,
            "title": "Author\u2019s contribution"
        },
        {
            "endOffset": 31505,
            "parents": [],
            "secId": "s0080",
            "sentence": "Although the VRRs at 1 month post-dose 2 were similar for the 3 groups, non-inferiority in terms of anti-gE humoral immune responses 1 month post-dose 2 was not demonstrated for the 0, 12-month schedule.",
            "startOffset": 31302,
            "title": "Discussion"
        },
        {
            "endOffset": 31091,
            "parents": [],
            "secId": "s0080",
            "sentence": "This is the first study to assess the immunogenicity and safety of 2 doses of the HZ/su vaccine administered at intervals longer than 2 months.",
            "startOffset": 30948,
            "title": "Discussion"
        },
        {
            "endOffset": 34802,
            "parents": [],
            "secId": "s0080",
            "sentence": "Participants were followed for 12 months post-dose 2 resulting in 20 months follow-up period for participants in the Gr 0\u20136 and 24 months follow-up period in the Gr 0\u201312.",
            "startOffset": 34632,
            "title": "Discussion"
        },
        {
            "endOffset": 33858,
            "parents": [],
            "secId": "s0080",
            "sentence": "At 12 months post-dose 2, anti-gE antibody GMCs were still in similar ranges and at least 11.6-fold the pre-vaccination levels.",
            "startOffset": 33731,
            "title": "Discussion"
        },
        {
            "endOffset": 29736,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "The median duration of solicited general symptoms was \u22642 days.",
            "startOffset": 29674,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 35304,
            "parents": [],
            "secId": "s0090",
            "sentence": "The results of this study were presented in part in:",
            "startOffset": 35252,
            "title": "Meeting"
        },
        {
            "endOffset": 16637,
            "parents": [],
            "secId": "s0005",
            "sentence": "Immunosenescence (age-dependent decrease in immunological competence) and immunodeficiency (caused by disease or medication) are the most important risk factors for developing HZ.",
            "startOffset": 16458,
            "title": "Introduction"
        },
        {
            "endOffset": 29892,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "22.7% of participants in Gr 0\u20132 and Gr 0\u20136 and 19.8% in Gr 0\u201312 reported at least 1 unsolicited symptom within the 30-day post-vaccination period (Table 2).",
            "startOffset": 29736,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 34362,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 34166,
                    "startOffset": 34160
                },
                "b0065": {
                    "endOffset": 34166,
                    "startOffset": 34160
                }
            },
            "secId": "s0080",
            "sentence": "The reactogenicity observed in this study is consistent with previous results in similar populations [5,13], with pain being the most frequently reported solicited local symptom, and fatigue, myalgia, and headache the most frequently reported solicited general symptoms, irrespective of dosing schedule.",
            "startOffset": 34059,
            "title": "Discussion"
        },
        {
            "endOffset": 34012,
            "parents": [],
            "secId": "s0080",
            "sentence": "The data by age sub-groups is a descriptive analysis, since the study was not intended and thus not powered to give confirmatory data per age sub-groups.",
            "startOffset": 33859,
            "title": "Discussion"
        },
        {
            "endOffset": 23586,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Grade 3 unsolicited AEs were also defined as \u201cpreventing normal, everyday activities\u201d.",
            "startOffset": 23500,
            "title": "Safety and reactogenicity assessment"
        },
        {
            "endOffset": 20011,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "HZ/su contains 50 \u03bcg of the VZV recombinant purified glycoprotein E (gE) antigen and the GSK proprietary AS01B Adjuvant System (containing 50 \u03bcg of 3-O-desacyl-4\u2032-monophosphoryl lipid A, 50 \u03bcg of Quillaja saponaria Molina, fraction 21 [licensed by GSK from Antigenics LLC, a wholly owned subsidiary of Agenus Inc., a Delaware, USA corporation] and liposomes).",
            "startOffset": 19652,
            "title": "Study vaccine"
        },
        {
            "endOffset": 20375,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Enrolled participants were randomized 1:1:1, to receive 2 doses of HZ/su according to a 0, 2-month (group [Gr] 0\u20132), 0, 6-month (Gr 0\u20136) or 0, 12-month (Gr 0\u201312) schedule, using an online centralized randomization system.",
            "startOffset": 20154,
            "title": "Randomization and masking"
        },
        {
            "endOffset": 28860,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Anti-gE GMCs and VRRs were similar across age groups (Table 1, Fig. S2).",
            "startOffset": 28788,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 20984,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The objective for the 0, 6-month schedule was met if the lower limit (LL) of the 97.5% confidence interval (CI) of the VRR for anti-gE enzyme-linked immunosorbent assay (ELISA) antibody concentrations at 1 month post-dose 2 was \u226560%.",
            "startOffset": 20751,
            "title": "Outcomes"
        },
        {
            "endOffset": 30054,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Unsolicited symptoms assessed by the investigators as related to vaccination were reported by 7.6% of participants in Gr 0\u20132, 4.2% in Gr 0\u20136 and 6.0% in Gr 0\u201312.",
            "startOffset": 29893,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 26315,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                },
                {
                    "id": "s0045",
                    "title": "Statistical analyses"
                }
            ],
            "secId": "s0055",
            "sentence": "The numbers of participants reporting SAEs, pIMDs, suspected HZ cases, and withdrawals due to AEs were also recorded.",
            "startOffset": 26198,
            "title": "Safety analyses"
        },
        {
            "endOffset": 30775,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Including the 2 fatalities, 4 participants were withdrawn from the study due to an SAE (Gr 0\u20132: 1; Gr 0\u20136: 2; Gr 0\u201312: 1).",
            "startOffset": 30653,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 33619,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 33618,
                    "startOffset": 33614
                }
            },
            "secId": "s0080",
            "sentence": "In other zoster vaccine trials, fold-rises in humoral immune responses compared to baseline have been suggested to correlate with protection against HZ and also to serve as a strong surrogate for protection due to other immune mechanisms [12].",
            "startOffset": 33376,
            "title": "Discussion"
        },
        {
            "endOffset": 20750,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "The first co-primary objective of the study was to evaluate the vaccine response rates (VRRs) for anti-gE humoral immune responses at 1 month post-dose 2 in study groups Gr 0\u20136 and Gr 0\u201312, in participants \u226550 YOA.",
            "startOffset": 20536,
            "title": "Outcomes"
        },
        {
            "endOffset": 29068,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Injection site pain was the most frequently reported solicited local symptom in all groups, reported by 76.5% (Gr 0\u20132), 79.8% (Gr 0\u20136) and 84.5% (Gr 0\u201312) of participants (Fig. 4).",
            "startOffset": 28888,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 22990,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Solicited local and general symptoms occurring within 7 days after each vaccination, and unsolicited adverse events (AEs), occurring within 30 days after each vaccination, were recorded.",
            "startOffset": 22804,
            "title": "Safety and reactogenicity assessment"
        },
        {
            "endOffset": 27195,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "One month post-dose 2, VRRs were 96.6%, 96.5% and 94.5% in Gr 0\u20132, Gr 0\u20136 and Gr 0\u201312, respectively (Fig. 2).",
            "startOffset": 27086,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 17363,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 17362,
                    "startOffset": 17359
                }
            },
            "secId": "s0005",
            "sentence": "In addition, humoral and cellular immune responses to HZ/su persisted substantially above pre-vaccination levels for 6 years [7].",
            "startOffset": 17234,
            "title": "Introduction"
        },
        {
            "endOffset": 28437,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "At 12 months post-dose 2, GMCs remained at least 11.6-fold higher than the pre-vaccination levels in all groups (Fig. 2).",
            "startOffset": 28316,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 17673,
            "parents": [],
            "secId": "s0005",
            "sentence": "Vaccine efficacy (VE) in preventing HZ was 97.2% in adults \u226550 YOA (ZOE-50) and 91.3% in adults \u226570 YOA (pooled ZOE-50 and ZOE-70 data).",
            "startOffset": 17537,
            "title": "Introduction"
        },
        {
            "endOffset": 35963,
            "parents": [],
            "secId": "s0095",
            "sentence": "All authors reviewed and commented on a draft version of the manuscript and approved the final approval for it to be submitted for publication.",
            "startOffset": 35820,
            "title": "Author\u2019s contribution"
        },
        {
            "endOffset": 17728,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 17727,
                    "startOffset": 17722
                },
                "b0045": {
                    "endOffset": 17727,
                    "startOffset": 17722
                }
            },
            "secId": "s0005",
            "sentence": "In both trials VE was similar across age strata [8,9].",
            "startOffset": 17674,
            "title": "Introduction"
        },
        {
            "endOffset": 23729,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "The causality of all other AEs was assessed by the investigator.",
            "startOffset": 23665,
            "title": "Safety and reactogenicity assessment"
        },
        {
            "endOffset": 20153,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "This was an open-label study.",
            "startOffset": 20124,
            "title": "Randomization and masking"
        },
        {
            "endOffset": 30875,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "None of the SAEs recorded in this study was assessed by the investigator as related to vaccination.",
            "startOffset": 30776,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 28788,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Similar low responders were not observed in Gr 0\u20132 or Gr 0\u20136.",
            "startOffset": 28727,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 35819,
            "parents": [],
            "secId": "s0095",
            "sentence": "CVA performed the analysis, HL, LC, BG, LO, CVA and TCH interpreted the data.",
            "startOffset": 35742,
            "title": "Author\u2019s contribution"
        },
        {
            "endOffset": 20096,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Study participants received 2 HZ/su doses of 0.5 mL each by intramuscular injection.",
            "startOffset": 20012,
            "title": "Study vaccine"
        },
        {
            "endOffset": 32115,
            "parents": [],
            "secId": "s0080",
            "sentence": "No issues with vaccine administration or sample collection were identified that would explain these results.",
            "startOffset": 32007,
            "title": "Discussion"
        },
        {
            "endOffset": 22320,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Anti-gE antibody concentrations were measured using an ELISA assay developed by GSK, with an assay cut-off of 97 milli-International Units (mIU)/mL.",
            "startOffset": 22172,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 23499,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "Grade 3 solicited symptoms were defined as \u201cpreventing normal everyday activity\u201d (pain, headache, fatigue, gastrointestinal symptoms, myalgia, shivering); surface diameter >100 mm (redness/swelling); tympanic/oral/axillary temperature >39.0 \u00b0C (fever).",
            "startOffset": 23247,
            "title": "Safety and reactogenicity assessment"
        },
        {
            "endOffset": 29215,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "Pain was also the most frequently reported grade 3 local symptom, reported by 5.9% (Gr 0\u20132), 5.0% (Gr 0\u20136) and 10.3% (Gr 0\u201312) study participants.",
            "startOffset": 29069,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 18417,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This was a phase III, randomized, multicenter, open-label study (NCT01751165) conducted in the United States and Estonia between 12 March 2013 and 08 April 2015 (study overview in Fig. S1).",
            "startOffset": 18228,
            "title": "Study design and participants"
        },
        {
            "endOffset": 24379,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0045",
            "sentence": "The according-to-protocol (ATP) cohort for immunogenicity/persistence included all participants who received both doses, for whom all eligibility criteria were met, who complied with the protocol, and for whom data concerning immunogenicity endpoint measures were available.",
            "startOffset": 24105,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 29366,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "The most frequently reported solicited general symptoms were fatigue, myalgia and headache (Fig. 4).",
            "startOffset": 29266,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 19400,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Chronic administration of immunosuppressants or other immune-modifying drugs within 6 months prior to the first vaccine dose, or any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy also resulted in exclusion.",
            "startOffset": 19108,
            "title": "Study design and participants"
        },
        {
            "endOffset": 29266,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0075",
            "sentence": "The median duration of local symptoms was \u22643 days.",
            "startOffset": 29216,
            "title": "Reactogenicity and safety"
        },
        {
            "endOffset": 23077,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0040",
            "sentence": "For all AEs, the Medical Dictionary for Regulatory Activities classification was used.",
            "startOffset": 22991,
            "title": "Safety and reactogenicity assessment"
        },
        {
            "endOffset": 19636,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study protocol, amendments, and informed consent forms were reviewed and approved by Independent Ethics Committees.",
            "startOffset": 19517,
            "title": "Study design and participants"
        },
        {
            "endOffset": 27345,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "The LL of the 97.5% CI of the VRR for anti-gE ELISA antibody concentrations at 1 month post-dose 2 was 90.4% in Gr 0\u20136 and 87.6% in Gr 0\u201312 (Fig. 2).",
            "startOffset": 27196,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 28171,
            "parents": [
                {
                    "id": "s0060",
                    "title": "Results"
                }
            ],
            "secId": "s0070",
            "sentence": "Anti-gE GMCs in Gr 0\u20132, Gr 0\u20136 and Gr 0\u201312 increased from pre-vaccination levels of 1079.1 mIU/mL, 1066.1 mIU/mL and 1019.4 mIU/mL to 44376.3 mIU/mL, 38153.7 mIU/mL and 37435.8 mIU/mL at 1 month post-dose 2, respectively (Fig. 2).",
            "startOffset": 27941,
            "title": "Immunogenicity"
        }
    ],
    "docId": "S0264410X17315785",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "himallal@yahoo.com",
                "first": "Himal",
                "initial": "H.",
                "last": "Lal"
            },
            {
                "email": "airi.poder@std.ee",
                "first": "Airi",
                "initial": "A.",
                "last": "Poder"
            },
            {
                "email": "laura.e.campora@gsk.com",
                "first": "Laura",
                "initial": "L.",
                "last": "Campora"
            },
            {
                "email": "brecht.r.geeraerts@gsk.com",
                "first": "Brecht",
                "initial": "B.",
                "last": "Geeraerts"
            },
            {
                "email": "lidia.oostvogels@gsk.com",
                "first": "Lidia",
                "initial": "L.",
                "last": "Oostvogels"
            },
            {
                "email": "carline.c.vanden-abeele@gsk.com",
                "first": "Carline",
                "initial": "C.",
                "last": "Vanden Abeele"
            },
            {
                "email": "thomas.heineman@genocea.com",
                "first": "Thomas C.",
                "initial": "T.C.",
                "last": "Heineman"
            }
        ],
        "doi": "10.1016/j.vaccine.2017.11.019",
        "firstpage": "148",
        "issn": "0264410X",
        "keywords": [
            "HZ/su",
            "Herpes zoster",
            "Immunogenicity",
            "Shingles",
            "Vaccine",
            "Varicella-zoster virus"
        ],
        "lastpage": "154",
        "openaccess": "Full",
        "pub_year": 2018,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study"
    }
}